# Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

> **NCT00702403** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Lymphoblastic Leukemia in Remission
- Blastic Phase Chronic Myelogenous Leukemia
- Childhood Acute Lymphoblastic Leukemia in Remission
- Childhood Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Phase Chronic Myelogenous Leukemia
- Philadelphia Positive Adult Acute Lymphoblastic Leukemia
- Philadelphia Positive Childhood Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Relapsing Chronic Myelogenous Leukemia
- Untreated Adult Acute Lymphoblastic Leukemia
- Untreated Childhood Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** nilotinib
- **DRUG:** imatinib mesylate
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00702403
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-14
- **Primary completion:** 2013-12
- **Final completion:** 2013-12-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00702403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00702403, "Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00702403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*